Dapagliflozin for type 1 diabetes: ensuring benefits outweigh the risks

This editorial discusses basis of EMA approval of dapagliflozin for type 1 diabetes, highlighting diabetic ketoacidosis was reported in a significant number of patients compared with placebo, and was the reason the USFDA did not approve dapagliflozin for use in type 1 diabetes.

SPS commentary:

The editorial also discusses precipitating factors identified for development of diabetic ketoacidosis, and recommending a process for reviewing the need for ongoing treatment with dapagliflozin, in terms of response and renal function.

Drug and Therapeutics Bulletin